Literature DB >> 8770102

RSR-13, an allosteric effector of hemoglobin, increases systemic and iliac vascular resistance in rats.

M P Kunert1, J F Liard, D J Abraham.   

Abstract

Tissue O2 delivery in excess of metabolic demand may be a factor in the development of high vascular resistance in experimental models of volume-expanded hypertension. This hypothesis was previously tested in rats with an exchange transfusion of red blood cells treated with inositol hexaphosphate or an intravenous infusion of RSR-4, allosteric effectors of hemoglobin. The binding of these drugs with hemoglobin effect a conformational change in the molecule, such that the affinity for O2 is reduced. However, in both preparations, the changes in vascular resistance could have been nonspecific. The present studies used intravenous infusions of RSR-13, which did not share some of the problematic characteristics of RSR-4 and inositol hexaphosphate. Conscious instrumented rats (an electromagnetic flow probe on ascending aorta or an iliac, mesenteric, or renal Doppler flow probe) were studied for 6 h after an RSR-13 infusion of 200 mg/kg in 15 min. This dose significantly increased arterial P50 (PO2 at which hemoglobin is 50% saturated) from 38 +/- 0.8 to 58 +/- 1.4 mmHg at 1 h after the start of the infusion. In the 3rd h cardiac output fell significantly from a control value of 358 +/- 33 to 243 +/- 24 ml.kg-1.min-1 and total peripheral resistance significantly increased from 0.31 +/- 0.03 to 0.43 +/- 0.04 mmHg.ml-1.kg.min. Cardiac output and P50 returned toward control over the next few hours. Neither cardiac output nor total peripheral resistance changed in the group of rats receiving vehicle alone. In a separate group of rats, iliac flow decreased significantly to 60% of control and iliac resistance increased to 160% of control. Iliac flow increased significantly in the group of rats that received vehicle only. Although the mechanism of these changes has not been established, these results suggest that a decreased O2 affinity leads to an increased total peripheral resistance and regional vascular resistance and support the hypothesis that O2 plays a role in the metabolic autoregulation of blood flow.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8770102     DOI: 10.1152/ajpheart.1996.271.2.H602

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  6 in total

1.  Identification of a novel class of covalent modifiers of hemoglobin as potential antisickling agents.

Authors:  A M Omar; M A Mahran; M S Ghatge; N Chowdhury; F H A Bamane; M E El-Araby; O Abdulmalik; M K Safo
Journal:  Org Biomol Chem       Date:  2015-06-14       Impact factor: 3.876

Review 2.  Modulating hemoglobin allostery for treatment of sickle cell disease: current progress and intellectual property.

Authors:  Piyusha P Pagare; Aref Rastegar; Osheiza Abdulmalik; Abdelsattar M Omar; Yan Zhang; Andrew Fleischman; Martin K Safo
Journal:  Expert Opin Ther Pat       Date:  2021-11-01       Impact factor: 6.714

3.  Phenoxyaromatic Acid Analogues as Novel Radiotherapy Sensitizers: Design, Synthesis and Biological Evaluation.

Authors:  Hongquan Zhang; Chunxi Wen; Bingting Li; Xinlin Yan; Yangrong Xu; Jialin Guo; Shi Hou; Jiajia Chang; Song Li; Junhai Xiao
Journal:  Molecules       Date:  2022-04-09       Impact factor: 4.927

Review 4.  Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin.

Authors:  Martin K Safo; Gregory J Kato
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-21       Impact factor: 3.722

Review 5.  Management of brain metastases.

Authors:  John H Suh; Samuel T Chao; Michael A Vogelbaum
Journal:  Curr Neurol Neurosci Rep       Date:  2009-05       Impact factor: 5.081

6.  Whole brain radiotherapy with radiosensitizer for brain metastases.

Authors:  Gustavo Arruda Viani; Gustavo Borges Manta; Ellen Carrara Fonseca; Ligia Issa De Fendi; Sergio Luis Afonso; Eduardo Jose Stefano
Journal:  J Exp Clin Cancer Res       Date:  2009-01-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.